GATC Health President Dr. Rahul Gupta to Speak at IndiaEdge 2025 in New Delhi

Irvine, California – December 3, 2025 – GATC Health, a technology company advancing drug discovery through advanced AI, today announced that its President, Dr. Rahul Gupta, has been invited to participate in IndiaEdge 2025: Policies for a Competitive India, organized by the Confederation of Indian Industry (CII). The event will take place from December 3–4, 2025, in New Delhi, India.

Dr. Gupta will speak on December 4 during the Healthcare & Pharma: Universal Access & Competitiveness session (1:00 p.m. – 2:30 p.m.), which will gather senior policymakers, industry leaders, and global experts to discuss strategic reforms and policy directions for India's healthcare sector. The session is designed to explore how innovation, technology, and global collaboration can enhance accessibility and competitiveness in healthcare and pharmaceuticals.

“India stands at a pivotal moment in its developmental journey,” said Dr. Gupta. “As the nation charts its next phase of growth, biotechnology and data-driven health innovation will play a transformative role in achieving universal access and better patient outcomes. GATC Health is honored to contribute to this important conversation.”

IndiaEdge 2025 serves as one of CII’s flagship policy platforms, convening thought leaders and government officials to deliberate on pathways for inclusive and sustainable national growth amid rapid technological and geopolitical change.

Dr. Gupta’s participation underscores GATC Health’s commitment to advancing global health solutions through multiomic science, predictive analytics, and cross-sector partnerships that expedite drug discovery and development, targeted capital deployment, and improved public health outcomes.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health's risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.